Clinical Trial Update: Treatment of Antibody-Mediated Rejection (ABMR) With CarBel [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating CarBel for treating antibody-mediated rejection in kidney transplant recipients; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• CarBel

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Kidney Transplant Rejection | Phase 2 | Status: NOT_YET_RECRUITING